You are here

Article Text

Article menu

Download PDFPDF

Correspondence response
Response to: ‘Treatment of systemic lupus erythematosus: don’t forget hydroxychloroquine’ by Michaud et al
Free
  1. Antonis Fanouriakis1,
  2. George Bertsias2,3,
  3. Dimitrios T Boumpas1
  1. 1 Rheumatology and Clinical Immunology, 4th Department of Internal Medicine, "Attikon" University Hospital, Athens, Greece
  2. 2 Department of Rheumatology, University Hospital of Heraklion, Heraklion, Greece
  3. 3 Laboratory of Autoimmunity-Inflammation, Institute of Molecular Biology and Biotechnology, Heraklion, Crete, Greece
  1. Correspondence to Dr Dimitrios T Boumpas, Medicine, National and Kapodestrian University of Athens, Athens 12462, Greece; boumpasd{at}uoc.gr

https://doi.org/10.1136/annrheumdis-2019-215817

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    We thank Michaud et al for their comment and thorough overview of the multiple benefits of hydroxychloroquine (HCQ) in systemic lupus erythematosus (SLE).1 We fully agree with the authors’ punchline that ‘HCQ is still in 2019 the cornerstone of the treatment of SLE’; a detailed description of its beneficial actions can be found in the Supplementary …

    View Full Text

    Linked Articles